High Dose IL 2 and Entinostat in RCC
High Dose IL 2 and Entinostat in RCC
Active, not recruiting · NCT03501381 · Registry updated 2023-09-01Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| High Dose IL 2 and Entinostat in RCC | Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Male Urogenital Diseases, Neoplasms by Histologic Type, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, adenocarcinoma, benign urinary system neoplasm, carcinoma, epithelial neoplasm, kidney cancer, kidney disorder, neoplasm, renal cell carcinoma, urinary system disorder | Active, not recruiting | Phase 2 | 2023-09-01 | NCT03501381 |
4 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Clinigen, Inc. | 3 |
| Indiana University | 297 |
| Roberto Pili | 1 |
| Syndax Pharmaceuticals | 16 |
5 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Hematology Oncology Clinic, LLC | Baton Rouge | United States | 1 |
| Indiana Univeristy Melvin and Bren Simon Cancer Center | Indianapolis | United States | 1 |
| Nebraska Methodist Hospital | Omaha | United States | 131 |
| Rush University Medical Center | Chicago | United States | 283 |
| Univeristy of Southern California | Los Angeles | United States | 1 |